Glaukos Corporation is a publicly traded ophthalmic medical technology and pharmaceutical company focused on glaucoma, corneal disorders, and retinal diseases. Founded in 1998 and headquartered in the U.S., the company operates at the intersection of micro-invasive surgical devices, drug delivery platforms, and corneal cross-linking systems. Its iStent inject W was the first FDA-approved micro-bypass stent for glaucoma treatment, and its pipeline holds 14 candidates across multiple therapeutic areas.
The security posture matters here: Glaukos deals in regulated medical device software, pharmaceutical R&D data, and global supply chain infrastructure spanning 62 countries. Think FDA compliance frameworks, patient data protection across international jurisdictions, intellectual property surrounding proprietary implant designs, and the integrity of manufacturing systems that produce devices implanted in human eyes. Over $700 million invested in R&D since 2018 means a substantial digital attack surface across research, clinical trial, and commercial operations.
The company reinvests roughly 30% of all sales back into R&D, maintaining active pipelines in both device and pharmaceutical development. Technical domains span ophthalmic device engineering, pharmaceutical formulation, drug-eluting implant technology, and corneal cross-linking systems. For cybersecurity roles, the threat model centers on protecting regulated health data, securing connected medical device ecosystems, safeguarding trade secrets in a competitive ophthalmic market, and maintaining compliance across a global regulatory landscape - without the option to get it wrong.
